文献速递眼底病与葡萄膜炎

0.2微克/天氟轻松玻璃体内植入剂治疗糖尿病性黄斑水肿的两年中期安全性结果:PALADIN观察性研究

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
PubMed 文献 · Br J Ophthalmol · 2020-05-27

PALADIN研究是一项为期3年的前瞻性观察性试验,报告0.2微克/天氟轻松(FAc)玻璃体内植入剂治疗糖尿病性黄斑水肿(DMO)的24个月中期安全性结果。95例既往接受过糖皮质激素治疗的患者(115只眼)数据显示,植入后平均眼压稳定,眼压相关手术少见,视力稳定(平均改善1-3个字母),中央亚区厚度(CST)显著降低,且每年所需DMO治疗次数减少。

要点

  • FAc植入后24个月内眼压相关手术少见,平均眼压稳定。
  • FAc植入后视力稳定(平均改善1-3个字母),CST显著降低。
  • FAc植入后每年所需DMO治疗次数减少,获益-风险比良好。

核心结论

  • FAc植入后24个月内眼压相关手术报告较少,视力稳定且CST降低,在DMO管理中具有良好获益-风险比,尤其适用于既往接受过糖皮质激素治疗的患者。

研究设计与样本

  • 前瞻性观察性研究24个月中期分析,纳入95例既往接受过糖皮质激素治疗的DMO患者(115只眼),收集FAc植入前最长36个月及植入后24个月数据。

主要发现

  • 总体人群FAc植入后平均眼压与植入前相比保持稳定。
  • FAc植入后眼压相关手术少见:植入前2例降眼压手术,植入后2例小梁成形术和4例降眼压手术。
  • FAc植入后平均视力稳定(平均改善1-3个字母),每年所需DMO治疗次数减少。
  • FAc植入后24个月平均CST显著降低(p<0.001),CST≤300微米患者百分比显著增加(p=0.041)。

关键数值与推荐

  • FAc植入剂剂量为0.2微克/天,玻璃体内持续低剂量释放糖皮质激素。
  • FAc植入后24个月平均CST显著降低(p<0.001),CST≤300微米患者百分比显著增加(p=0.041)。

临床怎么用

  • 对于既往接受过糖皮质激素治疗的DMO患者,FAc植入剂可稳定视力、降低CST并减少治疗频次,眼压相关手术风险较低。

局限性

  • 本文为24个月中期分析,最终3年结果尚未报告;样本量有限(95例患者,115只眼)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 0.2 µg/day fluocinolone acetonide (FAc) implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular oedema (DMO). This ongoing, 3-year, observational clinical trial provides long-term, 'real-world' safety results for the FAc implant in DMO. METHODS: This 24-month interim analysis of a prospective, observational study investigated patients with DMO receiving the commercially available intravitreal 0.2 µg/day FAc implant. The primary outcome was incidence of intraocular pressure (IOP)-lowering procedures. Other IOP-related signals and their relationship to previous corticosteroid exposure, best-corrected visual acuity, central subfield thickness (CST), ocular adverse events and frequency of other treatments were also measured. RESULTS: Data were collected from 95 previously steroid-challenged patients (115 study eyes) for up to 36 months pre-FAc and 24 months post-FAc implant. Mean IOP for the overall population remained stable post-FAc compared with pre-FAc implant. IOP-related procedures remained infrequent (two IOP-lowering surgeries pre-FAc; two trabeculoplasties and four IOP-lowering surgeries post-FAc). Mean visual acuity was stable post-FAc (mean improvement of 1-3 letters) and fewer DMO treatments were required per year following FAc implant. Mean CST was significantly reduced at 24 months post-FAc implant (p<0.001) and the percentage of patients with CST ≤300 µm was significantly increased (p=0.041). CONCLUSION: Few IOP-related procedures were reported during the 24 months post-FAc implant. Positive efficacy outcomes were noted after treatment, with stabilisation of vision and reduction in inflammation, demonstrated by CST. The FAc implant has a favourable benefit-risk profile in the management of DMO, especially when administered after a prior steroid challenge. TRIAL REGISTRATION NUMBER: NCT02424019.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Mansour SE, Kiernan DF, Roth DB, et al. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2020. PMID: 32461262. doi:10.1136/bjophthalmol-2020-315984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。